In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, as they kick off the first episode of a special three-part RhAPP Up series focused on key psoriatic arthritis updates from the 2026 EULAR Congress.

They discuss several key abstracts from the meeting, including a head-to-head trial comparing two different therapeutic approaches in active psoriatic arthritis and what the results may mean for treatment decisions in clinical practice. The conversation highlights how new data may help guide therapy selection and improve patient care.

The episode also reviews emerging data on a novel IL-17A inhibitor and its impact on patient-reported outcomes, including pain, fatigue, physical function, and quality of life. The conversation emphasizes the importance of aligning treatment goals with what matters most to patients, not just traditional clinical endpoints.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into evolving psoriatic arthritis treatment strategies, emerging biologic therapies, and the growing emphasis on precision medicine in inflammatory arthritis care.

Stay tuned for Part 2 of the RhAPP Up series and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.